Drug interaction potentials among different brands of grapefruit juice

Pharmazie

Volumn 63, Issue 2, 2008, Pages 144-146

  Uesawa, Yoshihiro ^a   Mohri, K ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6BETA HYDROXYTESTOSTERONE; CORTICOSTERONE; CYTOCHROME P450 3A; FUROCOUMARIN DERIVATIVE; TESTOSTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG OXIDATION; ENZYME ACTIVITY; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; HUMAN CELL; LIVER MICROSOME METABOLISM; REACTION TIME; TESTOSTERONE METABOLISM;

BEVERAGES; CITRUS PARADISI; CYTOCHROME P-450 CYP3A; FOOD HANDLING; FOOD-DRUG INTERACTIONS; HEAT; HUMANS; MICROSOMES, LIVER; PSORALENS; TESTOSTERONE;

EID: 39449110926     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2008.7219     Document Type: Article

References (19)

1. Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD (1993) Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 54: 589-594.
2. Bailey DG, Spence JD, Munoz C, Arnold JM (1991) Interaction of citrus juices with felodipine and nifedipine. Lancet 337: 268-269.
3. Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VJ (1999) Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 62: 25-31.
4. Dahan A, Altman H (2004) Food-drug interaction: grapefruit juice augments drug bioavailability-mechanism, extent and relevance. Eur J Clin Nutr 58: 1-9.
5. Fuhr U (1998) Drug interactions wifh grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Safety 18: 251-272.
6. García MJ, Reinoso RF, Sánchez Navarro A and Prous JR (2003) Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 25: 457-481.
7. Guengerich FP, Kim DH (1990) In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 11: 2275-2279.
8. Hagen RE, Dunlap WJ, Mizelle JW, Wender SH, Lime BJ, Albach RF, Griffiths FP (1965) A chromatographic-fluorometric method for determination of naringin, naringenin rutinoside, and related flavanone blycosides in grapefruit juice and juice sacs. Anal Biochem 12: 472-482.
9. He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF (1998) Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 11: 252-259.
10. Kane GC and Lipsky JJ (2000) Drug-grapefruit juice interactions. Mayo Clin Proc 75: 933-942.
11. Lundahl J, Regårdh CG, Edgar B, Johnsson G (1995) Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol 49: 61-67.
12. Mohri K, Uesawa Y (2001) Effects of furanocoumarin derivatives in grapefruit juice on nifedipine pharmacokinetics in rats. Pharm Res 18: 177-182.
13. Row E, Brown SA, Stachulski AV, Lennard MS (2006) Development of novel furanocoumarin dimers as potent and selective inhibitors of CYP3A4. Drug Metab Dispos 34: 324-330.
14. Sagir A, Schmitt M, Dilger K, Häussinger D (2003) Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology. Digestion 68: 41-48.
15. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB (1997) Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 25: 1228-1233.
16. Uesawa Y, Mohri K (2006a) UV-Irradiated grapefruit juice loses pharmacokinetic interaction with nifedipine in rats. Biol Pharm Bull 29: 1286-1289.
17. Uesawa Y, Mohri K (2006b) The use of heat treatment to eliminate drug interactions due to grapefruit juice. Biol Pharm Bull 29: 2274-2278.
18. Wacher VJ, Salphati L, Benet LZ (2001) Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 46: 89-102.
19. Watkins PB (1997) The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27: 161-170.